skip to content »

Neurology

Houston, Texas

The Cullen Building at Baylor College of Medicine.
Department of Neurology
not shown on screen

Mary Ann Thenganatt, M.D.

Assistant Professor of Neurology

Clinical Service Area

Neurology

Specialty

Movement Disorders
Parkinson's Disease
Tremors

Board Certification

American Board of Psychiatry and Neurology, Neurology

Clinic Appointments

713-798-7438

Consult

713-798-7438

Medical School

M.D., Boston University School of Medicine, Boston, Mass.

Undergraduate School

B.A., Boston University, Mass.

Internship

Internal Medicine, University of California, Los Angeles, Medical Center, Calif.

Residency

Neurology, Columbia University College of Physicians and Surgeons, New York, N.Y.

Clinical Fellowship

Movement Disorders, Columbia University College of Physicians and Surgeons, New York, N.Y.

Clinic Location

Baylor Neurology
Smith Tower
6550 Fannin, Suite 1801
Houston, Texas 77030

Contact Information

Mary Ann Thenganatt, M.D.
Department of Neurology
Baylor College of Medicine
One Baylor Plaza, MS NB302
Houston, Texas 77030

Tel: 713-798-7438
Fax: 713-798-6808

Journal Publications

  • Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 2014;71(4):499-504. [View journal article]
  • Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics. 2014;11(1):139-52. [View journal article]
  • Virmani T, Thenganatt MA, Goldman JS, Kubisch C, Greene PE, Alcalay RN. Oculogyric crises induced by levodopa in PLA2G6 parkinsonism-dystonia. Parkinsonism Relat Disord. 2014;20(2):245-7. [View journal article]
  • Thenganatt MA, Fahn S. Botulinum toxin for the treatment of movement disorders. Curr Neurol Neurosci Rep. 2012;12(4):399-409. [View journal article]
  • Thenganatt MA, Louis ED. Distinguishing essential tremor from Parkinson's disease: bedside tests and laboratory evaluations. Expert Rev Neurother. 2012;12(6):687-96. [View journal article]
  • Thenganatt MA, Louis ED. Personality profile in essential tremor: a case-control study. Parkinsonism Relat Disord. 2012;18(9):1042-4. [View journal article]
  • Thenganatt MA, Frucht SJ. Treatment options for sleep dysfunction in Parkinson's disease. Curr Treat Options Neurol. 2011;13(5):473-87. [View journal article]
  • Kim SJ, Prasad GV, Huang M, Nash MM, Famure O, Park J, et al. A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients. Transplantation. 2006;82(7):924-30. [View journal article]

Book Chapters and Other Publications

  • Thenganatt MA, Waters CH. Combined dopaminergic and nondopaminergic therapies. Advances in Parkinson's disease management. London: Future Medicine Ltd; 2012. p. 54-62.
  • Thenganatt MA, Frucht SJ. Dystonia, task-specific. In: Katie K, Leo Verhagen M, editors. Encyclopedia of movement disorders. Oxford: Academic Press; 2010. p. 386-389.
  • Thenganatt MA, Frucht SJ. Myoclonus. In: Katie K, Leo Verhagen M, editors. Encyclopedia of movement disorders. Oxford: Academic Press; 2010. p. 234-241.

Poster and Platform Presentations

  • Thenganatt MA, Srinivasan VM, Viswanathan A, Jimenez-Shahed J. Deep brain stimulation troubleshooting: Revision vs. reprogramming. Stereotact Funct Neurosurg. 2014;92(suppl 1): 52. [View poster]
  • Thenganatt MA, Alcalay RN, Vonsattel JPG, Hirano M, McKhann GM II, Greene PE. Multiple mitochondrial deletions and levodopa-responsive parkinsonism: A clinicopathological report. Mov Disord. 2012;27(Suppl 1):S397.
  • Thenganatt MA, Louis ED. Personality profile in essential tremor: A case control study. Neurology. 2012;78(Meeting Abstracts 1):P04.044.
  • Thenganatt M, Greene PE. Persistent dyskinesias after the discontinuation of levodopa and dopamine agonists in a patient with juvenile Parkinson's disease. Mov Disord. 2011;26 Suppl 2:S200-1.

E-mail this page to a friend